ABOS Overview

Kymera Therapeutics Inc.: The company's shares surged 9.58% to $73.00 in after-hours trading, driven by anticipation of results from the BroADen Phase 1b clinical trial for its oral STAT6 degrader for atopic dermatitis, set to be announced on December 8.

Ocular Therapeutix Inc.: Shares increased by 11.29% to $14.00 after hours, following recent progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, despite no new updates on Friday.

Predictive Oncology Inc.: The stock jumped 13.62% to $4.84 after hours, rebounding from a significant decline during the day, as the company regained compliance with Nasdaq's minimum stockholders' equity requirement.

Acumen Pharmaceuticals Inc.: Shares rose 3.23% to $1.92 after hours, following a presentation at the CTAD conference on improved delivery of Alzheimer's treatment antibodies, indicating positive long-term development prospects.

Financial Overview: Acumen Pharmaceuticals reported a cash balance of $136.1 million as of September 30, 2025, which is expected to support its clinical and operational activities into early 2027. The company experienced a decrease in both research and development expenses and net loss compared to the previous year.

Clinical Trials Update: The company anticipates non-clinical data for its Enhanced Brain Delivery (EBD™) program in early 2026 and expects topline results from the Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) for early Alzheimer's disease in late 2026.

Leadership Changes: Acumen appointed George Golumbeski, Ph.D., as the new Chairman of its Board of Directors, bringing over 30 years of biopharmaceutical experience to the company.

Product Development Focus: Acumen is focused on advancing sabirnetug, a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs), which are implicated in Alzheimer's disease, and is also exploring a subcutaneous formulation using Halozyme's drug delivery technology.

Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.